Cargando…

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer

This open‐label, phase Ib study (NCT02346370) assessed the effect of pegvorhyaluronidase alfa (PVHA; PEGPH20) on the plasma pharmacokinetics (PKs) and safety of docetaxel in 15 patients with stage IIIB/IV non‐small cell lung cancer (NSCLC). The docetaxel PK profile from this study was consistent wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heineman, Thomas, Baumgart, Megan, Nanavati, Charvi, Gabrail, Nash, Van Wart, Scott A., Mager, Donald E., Maneval, Daniel C., Fathallah, Anas M., Sekulovich, Rose E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504814/ https://www.ncbi.nlm.nih.gov/pubmed/33982408 http://dx.doi.org/10.1111/cts.13041

Ejemplares similares

Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts
por: Nanavati, Charvi, et al.
Publicado: (2017)

Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa
por: Wang, Song, et al.
Publicado: (2021)

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
por: Van Cutsem, Eric, et al.
Publicado: (2020)

Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy
por: Van Wart, Scott, et al.
Publicado: (2021)

Tumor Response to Stroma-Modifying Therapy: Magnetic Resonance Imaging Findings in Early-Phase Clinical Trials of Pegvorhyaluronidase alpha (PEGPH20)
por: Arias-Lorza, Andrés M., et al.
Publicado: (2023)

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
por: Hyun, Shin Young, et al.
Publicado: (2015)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric‐Onset Hypophosphatasia
por: Pan, Wei‐Jian, et al.
Publicado: (2021)

Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development
por: Abramova, Nadezda, et al.
Publicado: (2018)

Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series
por: Gabrail, Nash, et al.
Publicado: (2020)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
por: Costa, Marisa Boff, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome
por: Qi, Yulan, et al.
Publicado: (2014)

Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys
por: Pinkstaff, Jason, et al.
Publicado: (2023)

Effect of the Phragmitis rhizoma Aqueous Extract on the Pharmacokinetics of Docetaxel in Rats
por: Shin, Sarah, et al.
Publicado: (2019)

Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients
por: Wei, Jian, et al.
Publicado: (2022)

1088. A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)
por: Tarbell, Evan D, et al.
Publicado: (2021)

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
por: Lin, Hsien‐Hong, et al.
Publicado: (2021)

ALFA
por: Hiller, Karlheinz
Publicado: (2012)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014)

Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease
por: Abbas, Richat, et al.
Publicado: (2015)

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
por: Gabrail, Nashat, et al.
Publicado: (2015)

ALFA - Absolute Luminosity measurement For Atlas alias ALFA in ATLAS
por: Sykora, Tomas
Publicado: (2008)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
por: Mahlangu, Johnny, et al.
Publicado: (2021)

398 Pharmacokinetics of dalbavancin (DAL) in bone and associated tissues in patients undergoing orthopedic surgical procedures
por: Baldassarre, James, et al.
Publicado: (2014)

Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report
por: Yang, Liu, et al.
Publicado: (2015)

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
por: Faraj, Alan, et al.
Publicado: (2022)

Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy
por: Fr Brunsvig, Paal, et al.
Publicado: (2007)

P1007: PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH POLYCYTHEMIA VERA
por: Kirito, K., et al.
Publicado: (2022)

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders
por: Humaidan, P., et al.
Publicado: (2017)

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders
por: Humaidan, P., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
por: Kim, Aryun, et al.
Publicado: (2020)

Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects
por: Zhu, Min, et al.
Publicado: (2021)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2015)

Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile
por: Rafiei, Pedram, et al.
Publicado: (2017)

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
por: Vermunt, Marit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r07luekervoujntrrihnletp4p